跳至主要内容
临床试验/NCT02255045
NCT02255045已完成2 期

Evaluation of the Effect of a Vaginal Ring With Meloxicam on Primary Dysmenorrhea in Women of Childbearing Age

Laboratorios Andromaco S.A.1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2014年6月27日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
68
试验地点
1
主要终点
Efficacy: Percentage of primary dysmenorrhea reduction

研究概览

简要总结

The investigators propose that the sustained administration of a vaginal ring would have a better response with respect to pain and a better safety profile than the oral administration of a non-steroidal anti-inflammatory drug.

To assess the relief of the symptoms associated with dysmenorrhea, a specific survey was elaborated that also includes a Visual Analog Scale (VAS) to objectify and measure dysmenorrhea as is the case with McGill's Pain Questionnaire (MPQ).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Regular menstrual cycles on previous 3 months (24-35 days),
  • Primary dysmenorrhea on 3 previous months,
  • With tubal ligation or users of condom for contraception,
  • Hemoglobin of at least 11 g/dl,
  • Safety blood analysis in normal levels

排除标准

  • Secondary dysmenorrhea,
  • Users of hormonal contraceptives (2 months prior to the study) or intrauterine devices (IUDs) (1 month prior the study).
  • Allergy to any anti-inflammatory drug including meloxicam or diclofenac.
  • Allergy to silicon.
  • Pregnant or in lactation.
  • Women with untreated or decompensated endocrine disorders

研究组 & 干预措施

Dose 1 of meloxicam in vaginal ring

Experimental

2.4 g of meloxicam in a vaginal ring

干预措施: Placebo Oral (Drug)

Dose 2 of meloxicam in vaginal ring

Experimental

3.0 g of meloxicam in a vaginal ring

干预措施: Meloxicam (Drug)

Dose 1 of meloxicam in vaginal ring

Experimental

2.4 g of meloxicam in a vaginal ring

干预措施: Meloxicam (Drug)

Dose 2 of meloxicam in vaginal ring

Experimental

3.0 g of meloxicam in a vaginal ring

干预措施: Placebo Oral (Drug)

Oral non-steroidal anti-inflammatory drug

Active Comparator

Diclofenac potassium

干预措施: Diclofenac Potassium (Drug)

Oral non-steroidal anti-inflammatory drug

Active Comparator

Diclofenac potassium

干预措施: Placebo Vaginal (Drug)

Placebo vaginal ring and oral pill

Placebo Comparator

Placebo vaginal ring and placebo oral pill

干预措施: Placebo Oral (Drug)

Placebo vaginal ring and oral pill

Placebo Comparator

Placebo vaginal ring and placebo oral pill

干预措施: Placebo Vaginal (Drug)

结局指标

主要结局

Efficacy: Percentage of primary dysmenorrhea reduction

时间窗: 5 months

Change in primary dysmenorrhea using the VAS (0 = pain-free, 10 = maximum pain intensity) for the vaginal ring with meloxicam used during the perimenstrual period compared with a placebo ring.

次要结局

  • Minimum effective dose of meloxicam(5 months)
  • Efficacy: Comparison of meloxicam vaginal ring and oral diclofenac(5 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验